Kejun Ying

3 weeks ago | nature.com | Chiara Herzog |Kejun Ying |Raghav Sehgal |Waylon J. Hastings |Alexander Tyshkovskiy |Sara Hägg | +19 more

On 1–2 November 2024, the annual Biomarkers of Aging conference welcomed academic and industry scientists, and partners from governmental and nongovernmental organizations, to Harvard Medical School in Boston, USA, to discuss new insights into measuring and monitoring human aging, with the aim of clinical translation. In this Meeting Report, we summarize the conference and offer potential future directions for the Biomarkers of Aging Consortium and the longevity science community at large.

Nov 1, 2024 | weforum.org | Kejun Ying

Today, ageing is so much more than a number — and each of our organs has its own "true age". Using this information to bolster healthcare outcomes is key. Image: Getty ImagesPhD Candidate, Harvard Medical SchoolAgeing research is advancing quickly; we can now measure the "true" health of bodily organs like the heart and brain. Today, each of our organs has its own clock through which we can see its age and thus health. Turning that development into actionable healthcare is a key next step.

Oct 29, 2024 | nature.com | Kejun Ying

The ageing process involves complex biological changes, with epigenetic alterations playing a crucial part. Epigenetic clocks, the machine learning algorithms that predict biological age on the basis of DNA methylation patterns, have become popular computational tools in ageing research. These clocks can accurately estimate chronological age and have been associated with various health outcomes, including age-related diseases and mortality.

Oct 18, 2024 | nature.com | Kejun Ying |Jose Castro |José Castro |Alexander Tyshkovskiy |Sofiya Milman

AbstractWhile previous studies identified common genetic variants associated with longevity in centenarians, the role of the rare loss-of-function (LOF) mutation burden remains largely unexplored. Here, we investigated the burden of rare LOF mutations in Ashkenazi Jewish individuals from the Longevity Genes Project and LonGenity study cohorts using whole-exome sequencing data. We found that centenarians had a significantly lower burden (11-22%) of LOF mutations compared to controls.

Feb 14, 2024 | nature.com | Chiara Herzog |Jesse R. Poganik |Kejun Ying |Daniel Belsky |Albert T. Higgins-Chen |Alan Cohen | +12 more

AbstractThe search for biomarkers that quantify biological aging (particularly ‘omic’-based biomarkers) has intensified in recent years. Such biomarkers could predict aging-related outcomes and could serve as surrogate endpoints for the evaluation of interventions promoting healthy aging and longevity. However, no consensus exists on how biomarkers of aging should be validated before their translation to the clinic.